Contextlogic Inc. Stock Price, News & Analysis

LogicBio Therapeutics, Inc. (Nasdaq:LOGC) has successfully closed its public offering of 8,050,000 shares of common stock at $6.00 per share, raising gross proceeds of $48.3 million. The offering included the full exercise of the underwriters' option for additional shares. Funds will support clinical development of the LB-001 program, advancement of GeneRide and Next Generation Capsid platforms, and expand product candidates. Jefferies, Barclays, and William Blair served as joint book-running managers for the offering.

LogicBio Therapeutics (Nasdaq:LOGC) announced a public offering of 7,000,000 shares of common stock at $6.00 per share, aiming to raise approximately $42 million. The offering includes an option for underwriters to purchase an additional 1,050,000 shares. Proceeds will fund clinical development of LB-001, advance the GeneRide and Next Generation Capsid platforms, and support other corporate needs. The offering is scheduled to close on October 5, 2020, pending customary conditions.

LogicBio Therapeutics (Nasdaq: LOGC) announced its intention to conduct an underwritten public offering of common stock. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. The company plans to use net proceeds to support clinical development of LB-001, advance GeneRide and Next Generation Capsid platforms, and expand its product pipeline. The offering is subject to market conditions and conducted under an effective shelf registration statement. No assurance is provided on the completion or terms of the offering.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Fred Chereau will present at the Jefferies Virtual Gene Editing/Therapy Summit on October 2, 2020, at 11:30 AM ET. The presentation will be available via a live audio webcast on LogicBio’s website, with a replay accessible one hour post-event for 30 days. The company specializes in genome editing to treat rare pediatric diseases, utilizing its GeneRide platform for site-specific therapeutic transgene integration, aiming to meet significant medical needs.

LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines Conference on October 5, 2020, at 11 AM ET. The presentation will be available via live audio webcast on LogicBio's website, with a replay accessible one hour after the event for 30 days. LogicBio focuses on developing medicines for rare diseases in pediatric patients using its GeneRide™ technology platform, which enables site-specific integration of therapeutic transgenes without nucleases, aiming for lifelong expression.

LogicBio Therapeutics has received FDA clearance for its first investigational new drug application (IND) to initiate a Phase 1/2 clinical trial for LB-001, a treatment for methylmalonic acidemia (MMA). The SUNRISE trial will enroll pediatric patients aged 3 months to 12 years, focusing on safety and tolerability of LB-001. Initial dosing will start with patients aged 3-12 years, moving to younger cohorts as safety is established. The first patient enrollment is expected in early 2021, marking a significant milestone for the company and the genetic medicine sector.

LogicBio Therapeutics (Nasdaq:LOGC) reported its financial results for Q2 2020, showing a net loss of $8.2 million, or $0.35 per share, an improvement from $10 million, or $0.45 per share in Q2 2019. R&D expenses decreased to $5.9 million, primarily due to lower external development costs for LB-001, while G&A expenses rose to $3.0 million. The FDA has cleared the IND for LB-001 for treating methylmalonic acidemia, a significant milestone. The company expects to enroll the first patient in early 2021 and has a cash position of $36.7 million, expected to sustain operations into Q3 2021.

LogicBio Therapeutics (Nasdaq: LOGC) announced its 2020 Annual Meeting of Stockholders will proceed in a virtual-only format on June 19, 2020, at 9:00 a.m. E.T. This decision addresses ongoing public health concerns due to COVID-19. Stockholders can participate by registering in advance, with details available on the meeting’s website. Voting in advance is encouraged, and proxy materials are accessible. LogicBio remains committed to developing treatments for rare pediatric diseases using its proprietary GeneRide™ technology.

LogicBio Therapeutics (Nasdaq: LOGC) announced its participation in the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:00 a.m. ET. The event will feature a live audio webcast available on the company's website, with a replay accessible shortly after the presentation for 30 days.

LogicBio focuses on genome editing to develop medicines for rare pediatric diseases using its GeneRide technology, which enables precise integration of therapeutic transgenes for potentially lifelong expression. More information can be found at www.logicbio.com.